Novavax, Inc. (NASDAQ:NVAX) has received an average rating of “Hold” from the twelve research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $2.85.
NVAX has been the subject of several recent analyst reports. ValuEngine lowered shares of Novavax from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. BidaskClub lowered shares of Novavax from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Zacks Investment Research lowered shares of Novavax from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Ladenburg Thalmann Financial Services upgraded shares of Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price objective for the company in a research note on Wednesday, August 9th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $2.00 price objective on shares of Novavax in a research note on Friday, July 21st.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/16/novavax-inc-nvax-receives-average-recommendation-of-hold-from-analysts.html.
In other Novavax news, Director James F. Young sold 175,000 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $1.06, for a total transaction of $185,500.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.00% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in NVAX. Teachers Advisors LLC boosted its holdings in shares of Novavax by 4.2% in the 4th quarter. Teachers Advisors LLC now owns 455,686 shares of the biopharmaceutical company’s stock valued at $574,000 after acquiring an additional 18,519 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Novavax by 2.7% in the 1st quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 8,966 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Novavax in the 1st quarter valued at $157,000. Bank of New York Mellon Corp boosted its holdings in shares of Novavax by 0.9% in the 1st quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock valued at $1,555,000 after acquiring an additional 10,347 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Novavax by 41.9% in the 1st quarter. JPMorgan Chase & Co. now owns 3,708,105 shares of the biopharmaceutical company’s stock valued at $4,746,000 after acquiring an additional 1,095,388 shares during the last quarter. 45.17% of the stock is currently owned by institutional investors and hedge funds.
Novavax (NVAX) traded down 0.87% during midday trading on Friday, hitting $1.14. 8,497,869 shares of the stock were exchanged. Novavax has a 12 month low of $0.73 and a 12 month high of $2.47. The firm’s 50 day moving average price is $1.05 and its 200 day moving average price is $1.10. The company’s market cap is $330.49 million.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $6.70 million during the quarter, compared to analyst estimates of $6.15 million. Novavax had a negative net margin of 1,006.00% and a negative return on equity of 787.38%. Novavax’s revenue was up 168.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.29) EPS. On average, equities research analysts forecast that Novavax will post ($0.62) earnings per share for the current fiscal year.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.